The AdvisorShares Pure US Cannabis ETF (MSOS) is trading at its highest levels of 2026, a rally built on two converging catalysts: Trulieve Cannabis' move to the New York Stock Exchange and a Drug Enforcement Administration hearing set for later this month that could reshape how the federal government treats marijuana. As of May 31, MSOS posted a 103.7% one-year net asset value return, well ahead of the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8%. That kind of outperformance in a sector still locked out of federal banking channels tells you something about how much of this move is speculation on regulatory change rather than fundamentals catching up.
Trulieve's listing under the ticker TRLV matters beyond the headline. It required the company to separate its medical cannabis operations from its adult-use business, a structural change that let it clear the bar for a senior exchange listing rather than remaining stuck on over-the-counter markets where institutional capital tends to stay away. For operators watching this unfold from state-legal markets, the ripple effects touch far more than public equity - even the back-office tools multi-state operators depend on, from seed-to-sale compliance logs to platforms like dispensary management software connecticut relies on for regulatory reporting, become more valuable as capital access improves and companies scale compliance infrastructure to match investor expectations. A cleaner corporate structure, in other words, isn't just a listing requirement; it's a signal that the plumbing behind retail operations is getting more institutional. dispensary management software connecticut
What the DEA Hearing Actually Decides
The June 29 administrative hearing will examine whether cannabis, including adult-use products, should move from Schedule I to Schedule III. Proceedings are expected to run through no later than July 15. This is not the same as descheduling or legalization at the federal level - Schedule III still means cannabis remains a controlled substance, just one recognized as having accepted medical use with lower abuse potential than Schedule I drugs like heroin. What it does change, meaningfully, is tax treatment. Section 280E of the federal tax code currently bars cannabis companies from deducting ordinary business expenses - payroll, rent, marketing - because the plant remains Schedule I. Acting Attorney General Todd Blanche's April move to place state-licensed medical marijuana into Schedule III already eliminated that penalty for medical-only operators. A broader rescheduling that reaches adult-use products would extend that relief across the industry.
Balance Sheets, Banking, and the Uplisting Question
Cresco Labs' $50 million revolving credit facility from Needham Bank, announced this week, is a preview of what analysts expect more broadly if rescheduling proceeds: non-dilutive financing becoming available to cannabis operators who previously had to rely on expensive private debt or equity raises to fund acquisitions. Roth Capital has called the rescheduling order "extremely favorable," pointing to taxation relief, improved capital access, and a pathway toward more uplistings to senior exchanges. That's the bull case in plain terms. In practice, though, uplisting still requires operators to clean up corporate structures, satisfy exchange listing standards, and in some cases divest assets in states where federal-state conflicts remain unresolved - none of which happens overnight, regardless of how a hearing goes.
Reading the Upside Numbers With Some Caution
Analyst price targets compiled from Koyfin data show Verano with the steepest implied upside at 195%, followed by Jushi Holdings at 183% and Cresco Labs near 99%. Among MSOS' largest positions, Green Thumb Industries shows 70% upside, notably higher than Trulieve or Curaleaf despite those two carrying the largest weightings in the fund. Retail sentiment on platforms like Stocktwits runs "extremely bullish" on MSOS, Trulieve, and Green Thumb, with heavy message volume - a reminder that price targets and social sentiment are forward-looking bets, not settled outcomes. For dispensary operators and wholesalers watching from the ground level, the real test isn't where MSOS trades this month. It's whether rescheduling actually clears, whether banking access follows, and whether the compliance and tax relief investors are pricing in shows up in operators' actual cash flow statements.
